New hope for rare ovarian cancer: drug shrinks tumors after immunotherapy fails

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically diagnosed ovarian clear cell carcinoma * Patients who have progressed on imaging assessment after receiving immunotherapy, including anti-PD-1, PD-L1, and PD-1/PD-L1+CTLA4, and subsequently received Sacituzumab. * At least one measurable lesion as assessed by RECIST, version 1.1. * Life expectancy ≥ 12 months. * Normal renal an liver function, no myelosuppression. * Eastern Cooperative Oncology Group (ECOG) Performance Status score (PS score) 0-1. * Participants must have recovered from all toxicities resulting from previous treatment (recovery to \< grade 1 or protocol-specified inclusion criteria, based on a CTCAE 5.0 assessment), excluding alopecia. * Participants must be willing to participate in the study, be compliant, sign the informed consent form, and be able to adhere to protocol-specified visits and procedures. Exclusion Criteria: * Receipt of more than two lines of therapy after progression on immunotherapy. * Previous use of irinotecan or ADCs containing topoisomerase I inhibitors. * Presence or history of (non-infectious) interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment * Documented severe dry eye syndrome, severe meibomian gland disease and/or blepharitis, or a history of corneal disease that prevents delayed corneal healing. * Concomitant incomplete or complete intestinal obstruction, intestinal fistula of any grade, hydronephrosis that cannot be resolved with a ureteral stent, inflammatory bowel disease or brain metastases. * Organ transplant recipient. * ≥ Grade 3 venous embolism * Active infectious disease of any grade, including tuberculosis. * Previous history of pelvic or abdominal radiation therapy to any site. * Concurrent with other types of malignant tumors. * Mental status abnormalities. * Pregnant or lactating women; or patients of childbearing potential (male or female) who are unable to use effective medical contraception during the study period and for 6 months after the end of dosing. * Any other condition deemed inappropriate for participation in this study by the investigator.